Skip to main content

Eli Lilly vs Regeneron: Founders, CEOs and History

Eli Lilly was founded in 1876 by Colonel Eli Lilly and is led by David A. Ricks. Regeneron was founded in 1988 by Leonard S. Schleifer, George D. Yancopoulos and is led by Leonard S. Schleifer.

Company facts

Eli Lilly

Founded
1876
Headquarters
Indianapolis, Indiana
Current CEO
David A. Ricks
Employees
50,000

Regeneron

Founded
1988
Headquarters
Tarrytown, New York
Current CEO
Leonard S. Schleifer
Employees
15,410

Founders

Eli Lilly

  • Colonel Eli Lilly

    Following his military service and early experiences in the apothecary trade, Lilly worked in various pharmaceutical and business ventures, eventually amassing enough capital to strike out on his own.

Eli Lilly founders in full

Regeneron

  • Leonard S. Schleifer

    Leonard S. Schleifer founded Regeneron in 1988 and has led it as CEO since then, making him one of the longest-serving founder-CEOs in the S&P 500. He is also President and Board co-Chair.

  • George D. Yancopoulos

    George D. Yancopoulos joined Regeneron in 1989 as its founding scientist and serves as Board co-Chair, President and Chief Scientific Officer.

Regeneron founders in full

CEOs and their tenures

Eli Lilly

  1. Randall L. Tobias1993–1998

    Chairman and Chief Executive Officer

    Lilly launched Zyprexa and Humalog under him. Sidney Taurel succeeded him in 1998.

    Source
  2. Sidney Taurel1998–2008

    Former Chair and CEO

    Taurel's focus on targeted, personalized medicine anticipated the future direction of the pharmaceutical industry, shifting the company's research paradigm toward more precise and effective treatments.

    Source
  3. John C. Lechleiter2008–2016

    Chairman, President and CEO

    Lilly restructured and launched new products during his tenure. David Ricks became chief executive in 2017.

    Source
  4. David A. Ricks2017–present

    Chair and Chief Executive Officer

    Ricks's aggressive restructuring and cultural overhaul have been widely credited with revitalizing Eli Lilly's pipeline and driving a notable period of financial growth and market capitalization expansion.

    Source
Eli Lilly CEO history in full

Regeneron

  1. Christopher Fenimore

    Executive Vice President, Finance and Chief Financial Officer

    Oversees finance and capital allocation, including share repurchases and the dividend.

    Source
  2. Leonard S. Schleifer, M.D., Ph.D.1988–present

    Founder, Board co-Chair, President and CEO

    Has led Regeneron since 1988, from platform research to a company with $14.34 billion in FY2025 revenue.

    Source
  3. George D. Yancopoulos, M.D., Ph.D.1989–present

    Co-Founder, Board co-Chair, President and Chief Scientific Officer

    Runs Regeneron Research and the scientific portfolio.

    Source
Regeneron CEO history in full

Timeline: Eli Lilly and Regeneron side by side

  1. 1876Eli Lilly

    Eli Lilly Founded

    Colonel Eli Lilly founds the company in Indianapolis.

  2. 1923Eli Lilly

    Insulin Commercialization

    Lilly helps commercialize insulin at industrial scale, shaping its long-term diabetes identity.

  3. 1950Eli Lilly

    Antibiotic Expansion

    The company expands through antibiotics and broader prescription medicines.

  4. 1982Eli Lilly

    Humulin Approved

    Lilly introduces Humulin, one of the first recombinant DNA human insulin products.

  5. 1988Regeneron

    Regeneron is founded

    Leonard S. Schleifer founded Regeneron in New York in 1988; George D. Yancopoulos joined in 1989.

  6. 1991Regeneron

    Regeneron goes public

    The company listed on Nasdaq and funded a long period of platform research before becoming a commercial biotech.

  7. 2008Regeneron

    Arcalyst becomes Regeneron's first approved medicine

    Arcalyst validated Regeneron's trap-technology work and showed that the platform could produce approved therapies.

  8. 2011Regeneron

    EYLEA approval transforms the company

    EYLEA gave Regeneron a major ophthalmology franchise and moved the company into large-scale commercial operations.

  9. 2017Eli Lilly

    David Ricks Becomes CEO

    David A. Ricks becomes Chair, President, and CEO.

  10. 2017Regeneron

    Dupixent is approved

    Dupixent, developed with Sanofi, became a global immunology growth engine and a central part of Regeneron's collaboration economics.

  11. 2019Eli Lilly

    Loxo Oncology Acquired

    Lilly bought the cancer-drug developer Loxo Oncology in 2019 for about $8 billion.

  12. 2020Regeneron

    COVID-19 Antibody Authorization

    The FDA granted emergency use authorization to Regeneron's COVID-19 antibody treatment in November 2020.

  13. 2022Eli Lilly

    Mounjaro Approved

    Mounjaro receives U.S. approval for type 2 diabetes, beginning a major growth cycle.

  14. 2022Regeneron

    Checkmate Pharmaceuticals deal expands immuno-oncology

    Regeneron agreed to acquire Checkmate Pharmaceuticals for about $250 million to add the investigational TLR9 agonist vidutolimod.

  15. 2023Eli Lilly

    Zepbound Approved

    Zepbound receives U.S. approval for chronic weight management.

  16. 2023Regeneron

    Decibel Therapeutics acquisition closes

    Regeneron completed its acquisition of Decibel Therapeutics and added hearing-loss gene-therapy programs, including investigational DB-OTO in Phase 1/2 CHORD. It was not an approved therapy.

  17. 2023Regeneron

    EYLEA HD is approved

    The FDA approved EYLEA HD (aflibercept 8 mg) in August 2023, giving Regeneron a longer-dosing successor to EYLEA.

  18. 2024Regeneron

    Regeneron Cell Medicines is formed

    Regeneron acquired full development and commercialization rights to 2seventy bio's cell-therapy platforms and pipeline programs.

  19. 2025Eli Lilly

    Revenue Reaches $65.179B

    Lilly reports $65.179B in 2025 revenue and $20.640B in net income.

  20. 2025Eli Lilly

    First $1 Trillion Drugmaker

    Lilly's market value crosses $1 trillion on November 21, 2025, a first for a healthcare company.

  21. 2025Regeneron

    Revenue reaches $14.34 billion

    Regeneron reported FY2025 revenue of about $14.34 billion, with Dupixent growth offsetting pressure in the original EYLEA franchise.

  22. 2026Eli Lilly

    Foundayo Approved

    FDA approves Foundayo (orforglipron), Lilly's oral GLP-1 pill for obesity, on April 1, 2026.

  23. 2026Regeneron

    Q2 2026 revenue rises 17% to $4.3 billion

    Dupixent global sales reached $6.0 billion and the Sanofi development balance was fully repaid by the end of the quarter.

Acquisitions

Eli Lilly

  • Morphic Holding2024$3.2B
  • POINT Biopharma2023$1.4B
  • Prevail Therapeutics2021$1B
  • Loxo Oncology2019$8B
  • Elizabeth Arden1971Undisclosed
All Eli Lilly acquisitions

Regeneron

  • 2seventy bio platforms and pipeline rights2024$5M
  • Decibel Therapeutics2023$109M
  • Checkmate Pharmaceuticals2022$250M
All Regeneron acquisitions

Questions about Eli Lilly vs Regeneron

Who is the CEO of Eli Lilly and Company and Regeneron Pharmaceuticals, Inc.?

Eli Lilly and Company is led by David A. Ricks and Regeneron Pharmaceuticals, Inc. is led by Leonard S. Schleifer. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.

When was Eli Lilly and Company founded vs Regeneron Pharmaceuticals, Inc.?

Eli Lilly and Company was founded in 1876 — 112 years before Regeneron Pharmaceuticals, Inc., which was founded in 1988. Eli Lilly and Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Regeneron Pharmaceuticals, Inc..

How many employees does Eli Lilly and Company have compared to Regeneron Pharmaceuticals, Inc.?

Eli Lilly and Company employs approximately 50,000 people, while Regeneron Pharmaceuticals, Inc. employs approximately 15,410. Eli Lilly and Company has the larger workforce at 50,000 employees, compared to Regeneron Pharmaceuticals, Inc.'s 15,410. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).

Where are Eli Lilly and Company and Regeneron Pharmaceuticals, Inc. headquartered?

Both Eli Lilly and Company and Regeneron Pharmaceuticals, Inc. are headquartered in United States. Their local rules and tax obligations may still differ.

Who founded Eli Lilly and Company and Regeneron Pharmaceuticals, Inc.?

Eli Lilly and Company was founded by Colonel Eli Lilly. Regeneron Pharmaceuticals, Inc. was founded by Leonard S. Schleifer, George D. Yancopoulos.

Which company has a longer operating history — Eli Lilly and Company or Regeneron Pharmaceuticals, Inc.?

Eli Lilly and Company has been operating for approximately 150 years, making it the more established of the two companies. Regeneron Pharmaceuticals, Inc. has been in operation for around 38 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Eli Lilly vs Regeneron overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.